

ROBERT P. CASEY, JR.
PENNSYLVANIA

COMMITTEES:
FINANCE

HEALTH, EDUCATION,
LABOR, AND PENSIONS

SELECT COMMITTEE
ON INTELLIGENCE

SPECIAL COMMITTEE ON AGING

United States Senate

WASHINGTON, DC 20510

January 5, 2024

Susan Sholtis
President Nutrition
Reckitt
399 Interpace Parkway
Parsippany, NJ 07054

Dear Ms. Sholtis:

I write today to express my concern over the recent recall of six batches of Nutramigen Powder, a specialty infant formula for infants with cow's milk allergies, by Reckitt/Mead Johnson Nutrition due to potential contamination with *Cronobacter sakazakii*, which can cause life-threatening infections.


The recall includes six batches of Nutramigen Powder, totaling over 675,000 cans of infant formula, and the facility that produced these cans of formula remains under FDA inspection. While, fortunately, there have been no reports of illness, this news is alarming to parents and caregivers whose infants rely on this formula, and to families still reeling from the shortages and supply problems of the last two years. Further, since Nutramigen is a hypoallergenic formula, caregivers whose infants rely on Nutramigen have fewer alternatives available to them than families who purchase non-specialty formulas.

As we learned in 2022, ongoing communication directed at the families who rely on Nutramigen will be a key component of your response. Thus, I ask that you respond in writing to the following questions by January 19, 2024:

1. Has the facility where the formula was produced ceased production of Nutramigen during the FDA's inspection?
2. Are there other infant formulas produced at the same facility as the recalled infant formula, and if so, will their supply be compromised in any way due to the ongoing inspection by the FDA?
3. What impact will this recall have on the domestic supply of Nutramigen? Do you expect to see spot shortages, regional shortages, or shortages for WIC families in the states where you are the WIC provider?
4. Is Nutramigen Powder, or other forms of Nutramigen such as ready-to-feed bottles, produced at any additional facilities? Are those facilities located in the United States or in foreign countries? If needed, do they have the ability to increase production to meet demand?
5. What steps are you taking to mitigate future contamination of powdered infant formula during production and packaging?

If you have any questions about this request, please contact Sara Maskornick on my staff at sara_maskornick@help.senate.gov. I look forward to your timely response.

Sincerely,



Robert P. Casey, Jr.
United States Senator